{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:34:00Z","timestamp":1789842840157,"version":"4.0.1"},"reference-count":21,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Introduction: Tyrosine kinase inhibitors (TKIs) serve as the backbone in the management of chronic myelogenous leukemia and Philadelphia-positive Acute lymphoblastic Leukemia (Ph+ve ALL). With the growing use of TKIs, there has been an increase in adverse events related to these agents. Hereby, we present elderly women with Ph+ve ALL who developed recurrent pleural effusion, which was managed by switching the TKI and highlighting pleural effusion due to a third-generation TKI Bosutinib, adding to the minimal available literature. Case Description: Our patient is a 79-year-old female with Ph+ve ALL diagnosed in 2015 and started on treatment. She is also on TKI maintenance initially with Imatinib later shifted to second-generation TKIs. She started developing worsening dyspnea related to pulmonary toxicity related to TKI in the form of pleural effusion. Pleural effusion was initially managed with diuretics, later requiring thoracocentesis. Because of persistent pleural effusion, she was changed to multiple TKIs and finally started on Bosutinib. She even developed progressive pleural effusion while on Bosutinib which is managed by thoracocentesis. Conclusions: Through this case report, we would like to highlight refractory recurrent pleural effusion caused by bosutinib adding to the minimal available literature. In addition, we highlight the various treatment options in patients having cross-intolerance to various TKIs, especially pulmonary toxicity, and ponatinib might be a suitable option in such cases.<\/jats:p>","DOI":"10.3390\/hematolrep17010007","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T12:18:56Z","timestamp":1738585136000},"page":"7","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bosutinib-Induced Pleural Effusion\u2014Class Effect and Cross-Intolerance to All Tyrosine Kinase Inhibitors"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7238-1058","authenticated-orcid":false,"given":"Nikhil","family":"Vojjala","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Trinity Health Oakland Hospital, Pontiac, MI 48341, USA"},{"name":"Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI 48201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hizqueel A.","family":"Sami","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Trinity Health Oakland Hospital, Pontiac, MI 48341, USA"},{"name":"Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI 48201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0616-9141","authenticated-orcid":false,"given":"Nikhil Kumar","family":"Kotla","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Trinity Health Oakland Hospital, Pontiac, MI 48341, USA"},{"name":"Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI 48201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3895-9474","authenticated-orcid":false,"given":"Supriya","family":"Peshin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Norton Community Hospital, Norton, VA 24273, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanika","family":"Goyal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Trinity Health Oakland Hospital, Pontiac, MI 48341, USA"},{"name":"Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI 48201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya","family":"Kondaveety","sequence":"additional","affiliation":[{"name":"Department of Hospital Medicine, Cleveland Clinic Mercy Hospital, Canton, OH 44708, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9196-8425","authenticated-orcid":false,"given":"Rishab Rajendra","family":"Prabhu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Trinity Health Oakland Hospital, Pontiac, MI 48341, USA"},{"name":"Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI 48201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geetha","family":"Krishnamoorthy","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Trinity Health Oakland Hospital, Pontiac, MI 48341, USA"},{"name":"Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI 48201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2000279","DOI":"10.1183\/13993003.00279-2020","article-title":"Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors","volume":"56","author":"Weatherald","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e071456","DOI":"10.1136\/bmjopen-2022-071456","article-title":"Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): A retrospective pharmacovigilance study","volume":"13","author":"Huang","year":"2023","journal-title":"BMJ Open"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_6","first-page":"4236","article-title":"Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)","volume":"62","author":"Nagar","year":"2002","journal-title":"Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ddtec.2013.12.001","article-title":"New resistance mechanisms for small molecule kinase inhibitors of Abl kinase","volume":"11","author":"Modugno","year":"2014","journal-title":"Drug Discov. Today Technol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants","volume":"27","author":"Redaelli","year":"2008","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3563","article-title":"Role of ABL family kinases in cancer: From leukaemia to solid tumours","volume":"13","author":"Greuber","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.celrep.2015.12.080","article-title":"Kinase inhibitor profiling reveals unexpected opportunities to inhibit disease-associated mutant kinases","volume":"14","author":"Devarajan","year":"2016","journal-title":"Cell Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jtho.2016.11.2236","article-title":"Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: A meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR-mutated non\u2013small cell lung cancer","volume":"12","author":"Ding","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1701096","DOI":"10.1183\/13993003.01096-2017","article-title":"Dasatinib increases endothelial permeability leading to pleural effusion","volume":"51","author":"Phan","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1802472","DOI":"10.1183\/13993003.02472-2018","article-title":"Pulmonary arterial hypertension associated with protein kinase inhibitors: A pharmacovigilance\u2013pharmacodynamic study","volume":"53","author":"Cornet","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Darvishi, B., Farahmand, L., Eslami-S, Z., and Majidzadeh-A, K. (2017). NF-\u03baB as the main node of resistance to receptor tyrosine kinase inhibitors in triple-negative breast cancer. Tumor Biol., 39.","DOI":"10.1177\/1010428317706919"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.3324\/haematol.2017.171249","article-title":"Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: Final results of a phase I\/II study","volume":"103","author":"Cortes","year":"2018","journal-title":"Haematologica"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ajh.23728","article-title":"Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up","volume":"89","author":"Kim","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1007\/s00277-019-03802-y","article-title":"Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy","volume":"98","author":"Tiribelli","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1700930","DOI":"10.1183\/13993003.00930-2017","article-title":"Bosutinib-related pneumonitis","volume":"50","author":"Jutant","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/10781552221114070","article-title":"Bosutinib-induced massive pleural effusion: Cross-intolerance with all tyrosine kinase inhibitors","volume":"29","author":"Aslan","year":"2023","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_21","first-page":"154","article-title":"Bosutinib induced pleural effusions: Case report and review of tyrosine kinase inhibitors induced pulmonary toxicity","volume":"21","author":"Moguillansky","year":"2017","journal-title":"Respir. Med. Case Rep."}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/17\/1\/7\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:25:09Z","timestamp":1760027109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/17\/1\/7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["hematolrep17010007"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep17010007","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]}}}